Asked by: Manuela Perteghella (Liberal Democrat - Stratford-on-Avon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what consideration his Department has given to the potential role of a respiratory Modern Service Framework in reducing winter pressures on the NHS by improving outcomes for long-term respiratory conditions and short-term respiratory illnesses such as flu.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Modern service frameworks will define an aspirational, long-term outcome goal for a major condition and will then identify the best evidenced interventions and the support for delivery. Early priorities will include cardiovascular disease, severe mental illness, and the first ever service framework for frailty and dementia.
The Government will consider other long-term conditions for future waves of modern service frameworks, including respiratory conditions. The criteria for determining other conditions for future modern service frameworks will be based on where there is potential for rapid and significant improvements in quality of care and productivity. There has not, therefore, been a specific assessment made in relation to winter pressures.
NHS England, working with the Department, the UK Health Security Agency, and other partners, took action to reduce the impact of respiratory conditions on the National Health Service during the winter of 2025/26. Further details of the actions taken to reduce demand on acute services during winter is available at the following link:
https://www.england.nhs.uk/long-read/urgent-and-emergency-care-plan-2025-26/
Asked by: Manuela Perteghella (Liberal Democrat - Stratford-on-Avon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the number of emergency hospital admissions for respiratory conditions in (a) South Warwickshire, (b) the West Midlands region, and (c) England.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
NHS England routinely collects data on emergency admissions, including the chief complaint recorded at attendance.
In February 2026, there were 273,367 emergency admitted attendances in England, 14.9% of which recorded airway or breathing-related conditions as the chief complaint.
In the West Midlands, there were 57,805 emergency admitted attendances, with 15.8% relating to airway or breathing‑related conditions.
At the South Warwickshire NHS Foundation Trust, there were 2,025 emergency admitted attendances, 12.8% of which were for airway or breathing‑related conditions as the chief complaint.
Asked by: Manuela Perteghella (Liberal Democrat - Stratford-on-Avon)
Question to the Ministry of Housing, Communities and Local Government:
To ask the Secretary of State for Housing, Communities and Local Government, when detailed guidance and criteria for neighbourhood governance structures will be published.
Answered by Miatta Fahnbulleh - Parliamentary Under-Secretary (Housing, Communities and Local Government)
The government continues to engage with local government and the communities sector to ensure that we understand best practice. We will lay regulations and in due course.
Asked by: Manuela Perteghella (Liberal Democrat - Stratford-on-Avon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of patient access to specialist treatments for neuroendocrine cancer, including peptide receptor radionuclide therapy.
Answered by Sharon Hodgson - Parliamentary Under-Secretary (Department of Health and Social Care)
Improving the early diagnosis of rare cancers, including neuroendocrine cancers, is a priority for the Government. In February, the Government published the first ever National Cancer Plan with a dedicated chapter on rare cancers.
The Government is committed to transforming diagnostic services and will support the National Health Service to increase capacity to meet the demand for diagnostic services through investment in new capacity, including magnetic resonance imaging (MRI) and computed tomography (CT) scanners.
Neuroendocrine cancers benefit from system‑wide early diagnosis initiatives, including non‑specific symptoms pathways, and expanded diagnostic capacity through community diagnostic centres. NHS England has rolled out non‑specific symptom pathways nationally, designed to support patients whose symptoms do not clearly align with a single urgent cancer referral route, which particularly benefits rarer cancers such as neuroendocrine cancers.
NHS England recognises that cross sectional imaging, such as CT and/or MRI scanning in particular, play a crucial role in the diagnosis of neuroendocrine cancers. Whilst there is still more work to do, NHS England continues to prioritise and support access to CT/MRI scanning services through targeted capital investment which over the last five years has contributed to a 37% increase in CT scanners and a 33% increase in MRI scanners across the country.
In addition to imaging, the diagnosis of neuroendocrine cancer relies on a combination of biochemical tests, including blood and urine markers, and histopathological confirmation, typically obtained via biopsy. As part of broader efforts to strengthen diagnostic services, NHS England is investing in histopathology modernisation, including automation and digital pathology, to support improvements in diagnostic accuracy, timeliness, and equitable access to high-quality care.
The National Institute of Health and Care Excellence's (NICE’s) guideline makes recommendations by site of the suspected cancer that clinicians should use to guide referral for specialist opinion.
We will increase access to the best innovative cancer treatments for all. The Cancer Drugs Fund has helped to ensure that, according to industry data, patients in England receive new cancer treatments 50% faster than the European Union average, and it will continue to provide earlier access to promising new treatments. By April 2026, a joint process between NICE and the Medicines and Healthcare products Regulatory Agency will boost the speed of decisions on the licensing and appraisal of medicines, so that recommendations for the NHS to fund new drugs can be made faster.
Patients with rare cancers will benefit from a move to specialist, multi-disciplinary teams, that cover multiple healthcare providers. This will allow them to benefit from the input of specialist centres and access to the best evidence-based care. The Department is exploring novel procurement routes for diagnostics and treatments for rare cancers, such as advanced market commitments, to stimulate innovation in cancer treatments.
Where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan, and health and wellbeing information and support. This includes provision of information, empowering people to manage their care and the impact of their cancer. Personalised care ensures that each person’s care is planned holistically, covering mental and physical health as well as any practical or financial concerns. NHS England is committed to ensuring that all cancer patients get access to these interventions ensuring care is focused on what matters most to each person.
Cancer Alliances play a key role in transforming care and support for patients, working closely with the wider health and care system.
Asked by: Manuela Perteghella (Liberal Democrat - Stratford-on-Avon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure neuroendocrine cancer patients receive appropriate psychological, nutritional, and long‑term follow‑up support.
Answered by Sharon Hodgson - Parliamentary Under-Secretary (Department of Health and Social Care)
Improving the early diagnosis of rare cancers, including neuroendocrine cancers, is a priority for the Government. In February, the Government published the first ever National Cancer Plan with a dedicated chapter on rare cancers.
The Government is committed to transforming diagnostic services and will support the National Health Service to increase capacity to meet the demand for diagnostic services through investment in new capacity, including magnetic resonance imaging (MRI) and computed tomography (CT) scanners.
Neuroendocrine cancers benefit from system‑wide early diagnosis initiatives, including non‑specific symptoms pathways, and expanded diagnostic capacity through community diagnostic centres. NHS England has rolled out non‑specific symptom pathways nationally, designed to support patients whose symptoms do not clearly align with a single urgent cancer referral route, which particularly benefits rarer cancers such as neuroendocrine cancers.
NHS England recognises that cross sectional imaging, such as CT and/or MRI scanning in particular, play a crucial role in the diagnosis of neuroendocrine cancers. Whilst there is still more work to do, NHS England continues to prioritise and support access to CT/MRI scanning services through targeted capital investment which over the last five years has contributed to a 37% increase in CT scanners and a 33% increase in MRI scanners across the country.
In addition to imaging, the diagnosis of neuroendocrine cancer relies on a combination of biochemical tests, including blood and urine markers, and histopathological confirmation, typically obtained via biopsy. As part of broader efforts to strengthen diagnostic services, NHS England is investing in histopathology modernisation, including automation and digital pathology, to support improvements in diagnostic accuracy, timeliness, and equitable access to high-quality care.
The National Institute of Health and Care Excellence's (NICE’s) guideline makes recommendations by site of the suspected cancer that clinicians should use to guide referral for specialist opinion.
We will increase access to the best innovative cancer treatments for all. The Cancer Drugs Fund has helped to ensure that, according to industry data, patients in England receive new cancer treatments 50% faster than the European Union average, and it will continue to provide earlier access to promising new treatments. By April 2026, a joint process between NICE and the Medicines and Healthcare products Regulatory Agency will boost the speed of decisions on the licensing and appraisal of medicines, so that recommendations for the NHS to fund new drugs can be made faster.
Patients with rare cancers will benefit from a move to specialist, multi-disciplinary teams, that cover multiple healthcare providers. This will allow them to benefit from the input of specialist centres and access to the best evidence-based care. The Department is exploring novel procurement routes for diagnostics and treatments for rare cancers, such as advanced market commitments, to stimulate innovation in cancer treatments.
Where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan, and health and wellbeing information and support. This includes provision of information, empowering people to manage their care and the impact of their cancer. Personalised care ensures that each person’s care is planned holistically, covering mental and physical health as well as any practical or financial concerns. NHS England is committed to ensuring that all cancer patients get access to these interventions ensuring care is focused on what matters most to each person.
Cancer Alliances play a key role in transforming care and support for patients, working closely with the wider health and care system.
Asked by: Manuela Perteghella (Liberal Democrat - Stratford-on-Avon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether neuroendocrine cancers are included in NHS England’s wider early cancer diagnosis initiatives, including the Faster Diagnosis Standard.
Answered by Sharon Hodgson - Parliamentary Under-Secretary (Department of Health and Social Care)
Improving the early diagnosis of rare cancers, including neuroendocrine cancers, is a priority for the Government. In February, the Government published the first ever National Cancer Plan with a dedicated chapter on rare cancers.
The Government is committed to transforming diagnostic services and will support the National Health Service to increase capacity to meet the demand for diagnostic services through investment in new capacity, including magnetic resonance imaging (MRI) and computed tomography (CT) scanners.
Neuroendocrine cancers benefit from system‑wide early diagnosis initiatives, including non‑specific symptoms pathways, and expanded diagnostic capacity through community diagnostic centres. NHS England has rolled out non‑specific symptom pathways nationally, designed to support patients whose symptoms do not clearly align with a single urgent cancer referral route, which particularly benefits rarer cancers such as neuroendocrine cancers.
NHS England recognises that cross sectional imaging, such as CT and/or MRI scanning in particular, play a crucial role in the diagnosis of neuroendocrine cancers. Whilst there is still more work to do, NHS England continues to prioritise and support access to CT/MRI scanning services through targeted capital investment which over the last five years has contributed to a 37% increase in CT scanners and a 33% increase in MRI scanners across the country.
In addition to imaging, the diagnosis of neuroendocrine cancer relies on a combination of biochemical tests, including blood and urine markers, and histopathological confirmation, typically obtained via biopsy. As part of broader efforts to strengthen diagnostic services, NHS England is investing in histopathology modernisation, including automation and digital pathology, to support improvements in diagnostic accuracy, timeliness, and equitable access to high-quality care.
The National Institute of Health and Care Excellence's (NICE’s) guideline makes recommendations by site of the suspected cancer that clinicians should use to guide referral for specialist opinion.
We will increase access to the best innovative cancer treatments for all. The Cancer Drugs Fund has helped to ensure that, according to industry data, patients in England receive new cancer treatments 50% faster than the European Union average, and it will continue to provide earlier access to promising new treatments. By April 2026, a joint process between NICE and the Medicines and Healthcare products Regulatory Agency will boost the speed of decisions on the licensing and appraisal of medicines, so that recommendations for the NHS to fund new drugs can be made faster.
Patients with rare cancers will benefit from a move to specialist, multi-disciplinary teams, that cover multiple healthcare providers. This will allow them to benefit from the input of specialist centres and access to the best evidence-based care. The Department is exploring novel procurement routes for diagnostics and treatments for rare cancers, such as advanced market commitments, to stimulate innovation in cancer treatments.
Where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan, and health and wellbeing information and support. This includes provision of information, empowering people to manage their care and the impact of their cancer. Personalised care ensures that each person’s care is planned holistically, covering mental and physical health as well as any practical or financial concerns. NHS England is committed to ensuring that all cancer patients get access to these interventions ensuring care is focused on what matters most to each person.
Cancer Alliances play a key role in transforming care and support for patients, working closely with the wider health and care system.
Asked by: Manuela Perteghella (Liberal Democrat - Stratford-on-Avon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure timely patient access to innovative treatments for rare cancers, including neuroendocrine cancers.
Answered by Sharon Hodgson - Parliamentary Under-Secretary (Department of Health and Social Care)
Improving the early diagnosis of rare cancers, including neuroendocrine cancers, is a priority for the Government. In February, the Government published the first ever National Cancer Plan with a dedicated chapter on rare cancers.
The Government is committed to transforming diagnostic services and will support the National Health Service to increase capacity to meet the demand for diagnostic services through investment in new capacity, including magnetic resonance imaging (MRI) and computed tomography (CT) scanners.
Neuroendocrine cancers benefit from system‑wide early diagnosis initiatives, including non‑specific symptoms pathways, and expanded diagnostic capacity through community diagnostic centres. NHS England has rolled out non‑specific symptom pathways nationally, designed to support patients whose symptoms do not clearly align with a single urgent cancer referral route, which particularly benefits rarer cancers such as neuroendocrine cancers.
NHS England recognises that cross sectional imaging, such as CT and/or MRI scanning in particular, play a crucial role in the diagnosis of neuroendocrine cancers. Whilst there is still more work to do, NHS England continues to prioritise and support access to CT/MRI scanning services through targeted capital investment which over the last five years has contributed to a 37% increase in CT scanners and a 33% increase in MRI scanners across the country.
In addition to imaging, the diagnosis of neuroendocrine cancer relies on a combination of biochemical tests, including blood and urine markers, and histopathological confirmation, typically obtained via biopsy. As part of broader efforts to strengthen diagnostic services, NHS England is investing in histopathology modernisation, including automation and digital pathology, to support improvements in diagnostic accuracy, timeliness, and equitable access to high-quality care.
The National Institute of Health and Care Excellence's (NICE’s) guideline makes recommendations by site of the suspected cancer that clinicians should use to guide referral for specialist opinion.
We will increase access to the best innovative cancer treatments for all. The Cancer Drugs Fund has helped to ensure that, according to industry data, patients in England receive new cancer treatments 50% faster than the European Union average, and it will continue to provide earlier access to promising new treatments. By April 2026, a joint process between NICE and the Medicines and Healthcare products Regulatory Agency will boost the speed of decisions on the licensing and appraisal of medicines, so that recommendations for the NHS to fund new drugs can be made faster.
Patients with rare cancers will benefit from a move to specialist, multi-disciplinary teams, that cover multiple healthcare providers. This will allow them to benefit from the input of specialist centres and access to the best evidence-based care. The Department is exploring novel procurement routes for diagnostics and treatments for rare cancers, such as advanced market commitments, to stimulate innovation in cancer treatments.
Where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan, and health and wellbeing information and support. This includes provision of information, empowering people to manage their care and the impact of their cancer. Personalised care ensures that each person’s care is planned holistically, covering mental and physical health as well as any practical or financial concerns. NHS England is committed to ensuring that all cancer patients get access to these interventions ensuring care is focused on what matters most to each person.
Cancer Alliances play a key role in transforming care and support for patients, working closely with the wider health and care system.
Asked by: Manuela Perteghella (Liberal Democrat - Stratford-on-Avon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what guidance is issued to GPs on recognising symptoms of neuroendocrine cancers.
Answered by Sharon Hodgson - Parliamentary Under-Secretary (Department of Health and Social Care)
Improving the early diagnosis of rare cancers, including neuroendocrine cancers, is a priority for the Government. In February, the Government published the first ever National Cancer Plan with a dedicated chapter on rare cancers.
The Government is committed to transforming diagnostic services and will support the National Health Service to increase capacity to meet the demand for diagnostic services through investment in new capacity, including magnetic resonance imaging (MRI) and computed tomography (CT) scanners.
Neuroendocrine cancers benefit from system‑wide early diagnosis initiatives, including non‑specific symptoms pathways, and expanded diagnostic capacity through community diagnostic centres. NHS England has rolled out non‑specific symptom pathways nationally, designed to support patients whose symptoms do not clearly align with a single urgent cancer referral route, which particularly benefits rarer cancers such as neuroendocrine cancers.
NHS England recognises that cross sectional imaging, such as CT and/or MRI scanning in particular, play a crucial role in the diagnosis of neuroendocrine cancers. Whilst there is still more work to do, NHS England continues to prioritise and support access to CT/MRI scanning services through targeted capital investment which over the last five years has contributed to a 37% increase in CT scanners and a 33% increase in MRI scanners across the country.
In addition to imaging, the diagnosis of neuroendocrine cancer relies on a combination of biochemical tests, including blood and urine markers, and histopathological confirmation, typically obtained via biopsy. As part of broader efforts to strengthen diagnostic services, NHS England is investing in histopathology modernisation, including automation and digital pathology, to support improvements in diagnostic accuracy, timeliness, and equitable access to high-quality care.
The National Institute of Health and Care Excellence's (NICE’s) guideline makes recommendations by site of the suspected cancer that clinicians should use to guide referral for specialist opinion.
We will increase access to the best innovative cancer treatments for all. The Cancer Drugs Fund has helped to ensure that, according to industry data, patients in England receive new cancer treatments 50% faster than the European Union average, and it will continue to provide earlier access to promising new treatments. By April 2026, a joint process between NICE and the Medicines and Healthcare products Regulatory Agency will boost the speed of decisions on the licensing and appraisal of medicines, so that recommendations for the NHS to fund new drugs can be made faster.
Patients with rare cancers will benefit from a move to specialist, multi-disciplinary teams, that cover multiple healthcare providers. This will allow them to benefit from the input of specialist centres and access to the best evidence-based care. The Department is exploring novel procurement routes for diagnostics and treatments for rare cancers, such as advanced market commitments, to stimulate innovation in cancer treatments.
Where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan, and health and wellbeing information and support. This includes provision of information, empowering people to manage their care and the impact of their cancer. Personalised care ensures that each person’s care is planned holistically, covering mental and physical health as well as any practical or financial concerns. NHS England is committed to ensuring that all cancer patients get access to these interventions ensuring care is focused on what matters most to each person.
Cancer Alliances play a key role in transforming care and support for patients, working closely with the wider health and care system.
Asked by: Manuela Perteghella (Liberal Democrat - Stratford-on-Avon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to improve the early diagnosis of neuroendocrine cancers.
Answered by Sharon Hodgson - Parliamentary Under-Secretary (Department of Health and Social Care)
Improving the early diagnosis of rare cancers, including neuroendocrine cancers, is a priority for the Government. In February, the Government published the first ever National Cancer Plan with a dedicated chapter on rare cancers.
The Government is committed to transforming diagnostic services and will support the National Health Service to increase capacity to meet the demand for diagnostic services through investment in new capacity, including magnetic resonance imaging (MRI) and computed tomography (CT) scanners.
Neuroendocrine cancers benefit from system‑wide early diagnosis initiatives, including non‑specific symptoms pathways, and expanded diagnostic capacity through community diagnostic centres. NHS England has rolled out non‑specific symptom pathways nationally, designed to support patients whose symptoms do not clearly align with a single urgent cancer referral route, which particularly benefits rarer cancers such as neuroendocrine cancers.
NHS England recognises that cross sectional imaging, such as CT and/or MRI scanning in particular, play a crucial role in the diagnosis of neuroendocrine cancers. Whilst there is still more work to do, NHS England continues to prioritise and support access to CT/MRI scanning services through targeted capital investment which over the last five years has contributed to a 37% increase in CT scanners and a 33% increase in MRI scanners across the country.
In addition to imaging, the diagnosis of neuroendocrine cancer relies on a combination of biochemical tests, including blood and urine markers, and histopathological confirmation, typically obtained via biopsy. As part of broader efforts to strengthen diagnostic services, NHS England is investing in histopathology modernisation, including automation and digital pathology, to support improvements in diagnostic accuracy, timeliness, and equitable access to high-quality care.
The National Institute of Health and Care Excellence's (NICE’s) guideline makes recommendations by site of the suspected cancer that clinicians should use to guide referral for specialist opinion.
We will increase access to the best innovative cancer treatments for all. The Cancer Drugs Fund has helped to ensure that, according to industry data, patients in England receive new cancer treatments 50% faster than the European Union average, and it will continue to provide earlier access to promising new treatments. By April 2026, a joint process between NICE and the Medicines and Healthcare products Regulatory Agency will boost the speed of decisions on the licensing and appraisal of medicines, so that recommendations for the NHS to fund new drugs can be made faster.
Patients with rare cancers will benefit from a move to specialist, multi-disciplinary teams, that cover multiple healthcare providers. This will allow them to benefit from the input of specialist centres and access to the best evidence-based care. The Department is exploring novel procurement routes for diagnostics and treatments for rare cancers, such as advanced market commitments, to stimulate innovation in cancer treatments.
Where appropriate, every person diagnosed with cancer will have access to personalised care, including needs assessment, a care plan, and health and wellbeing information and support. This includes provision of information, empowering people to manage their care and the impact of their cancer. Personalised care ensures that each person’s care is planned holistically, covering mental and physical health as well as any practical or financial concerns. NHS England is committed to ensuring that all cancer patients get access to these interventions ensuring care is focused on what matters most to each person.
Cancer Alliances play a key role in transforming care and support for patients, working closely with the wider health and care system.
Asked by: Manuela Perteghella (Liberal Democrat - Stratford-on-Avon)
Question to the Ministry of Defence:
To ask the Secretary of State for Defence, if his department will provide a timetable for reviewing the continued use of real bearskin in military ceremonial uniforms.
Answered by Luke Pollard - Minister of State (Ministry of Defence)
The current cost of a bearskin cap is £2,460 including VAT. Whilst the longevity of caps varies depending on how they are maintained, this can be up to and in excess of 20 years.
The Department has not yet identified a synthetic alternative that meets the standards required to provide an effective replacement for bearskin ceremonial caps. However, the Ministry of Defence remains committed to finding a synthetic alternative and continues to welcome submissions of test results, from a testing house accredited by the United Kingdom Accreditation Service, on synthetic alternatives that meet our criteria for a suitable, affordable and sustainable alternative to bearskin caps.